Cetera Advisors LLC Liquidia Corp Transaction History

Cetera Advisors LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$11.35 - $16.73 $204 - $301	18 Added 0.06%	29,692 $437,000
Q4 2023 Feb 13, 2024	BUY	$5.77 - $12.19 $80 - $170	14 Added 0.05%	29,674 $356,000
Q3 2023 Nov 14, 2023	BUY	$6.27 - $8.15 $200 - $260	32 Added 0.11%	29,660 $188,000
Q2 2023 Aug 09, 2023	BUY	$6.63 - $9.9 $196,433 - $293,317	29,628 New	29,628 $232,000

162

36M

1.79M

380K

Ticker LQDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,362,300
Market Cap $709M
Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...

Get notified when there are updates to the investment portfolio of Cetera Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Cetera Advisors LLC with notifications on news.